FOR IMMEDIATE RELEASE
2 November 2007

2007 ANNUAL GENERAL MEETING

QRxPharma (ASX: QRX), a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management and other central nervous system (CNS) disorders, conducted its Annual General Meeting today at Four Points Hotel, 161 Sussex Street, Sydney, commencing at 10.00am. Please find attached the addresses delivered by Dr Peter Farrell (Chairman) and Dr John Holaday (Managing Director and Chief Executive Officer).

For further information please contact:

Dr John Holaday, Managing Director and CEO
+612 9492 8021 (office)
+61 401 988 444 (mobile)

About QRxPharma
QRxPharma (ASX: QRX) is a clinical-stage specialty pharmaceutical company with a core focus on the development and commercialisation of pain therapy products. The Company's lead pain products are a patented combination of existing pain therapies and have a well-defined path to regulatory approval and sales. QRxPharma's lead pain product, Q8003IR, is intended to begin its Phase 3 clinical program in late 2007. The Company's other clinical and preclinical pipeline products include a controlled release version of Q8003IR, called Q8011CR, and other development projects in the fields of neurodegenerative diseases and venomics.

Chairman's Address – Dr Peter Farrell
2 November 2007

Ladies and gentlemen, when the Company chose to raise capital via an IPO in May of this year our investment proposition was clear and compelling. Our Offer invited potential investors to join us in funding the development of QRxPharma's clinical stage pipeline of pharmaceuticals.

Underpinned by cornerstone investors Innovation Capital and Kestrel Capital, we successfully raised $50 million and on behalf of the Board I acknowledge the continuing commitment of our original VC investors and welcome the support of our new shareholders who took up our Offer to invest in QRxPharma.

The Offer was fully underwritten by JP Morgan, with Patersons and Ord Minnett as Co-Managers. The Board was very pleased with the positive response from investors and the Offer was significantly oversubscribed. On listing, QRxPharma was capitalised at $150 million.

The funds raised through the Offer are being used to support the Company's Drug Development Expenditure Program. The immediate goals of the Program are to conduct Phase 3 clinical trials of our dual opioid therapy (Q8003IR) for the treatment of moderate to severe pain and to submit a successful New Drug Application (or NDA) to the US FDA.

Following the FDA's expected approval of the NDA and the completion of two Phase 3 clinical trials in 2008 and 2009, first sales of Q8003IR are scheduled to occur in the US in 2010.

Another priority of the Expenditure Program is the advancement of clinical trials for Q8011CR, our oral controlled release capsule which will reduce the number of opioid doses required per day and offer significant other benefits to patients and prescribers. Q8011CR is due to complete Phase 1 studies by mid-2008.

QRxPharma's Managing Director and CEO Dr John Holaday will update you shortly on the Company's operations, especially as to progress in relation to our dual opioid pain management therapies and on the status of research and development into our other clinical and pre-clinical drugs, notably the Torsin Platform for Central Nervous System disorders.

As we continue to pass the required regulatory and trial milestones on the road to the US marketplace we have fully justified our investors' faith in the Company's ability to deliver on the undertakings given in QRxPharma's Prospectus.

Our financial performance is in line with that set out in the Prospectus and cash utilisation at the end of the September quarter was tracking on forecast.

The Board believes that the Company's retained $44 million in cash reserves and investments are sufficient to fully fund the Q8001IR Phase 3 clinical trials as well as the NDA to the FDA, clearing the route to commercialisation.

QRxPharma is fortunate in having an experienced and committed Board and executive team, led by John with Doug Saltel as COO, but we also benefit greatly from the wisdom and extensive credentials of our non-executive Scientific Advisory Board.

This body of distinguished clinicians has been enhanced in recent months by the appointments of Dr Lester Crawford and of Dr Gavril Pasternak. Dr Crawford is a former head of the FDA.

Ladies and gentlemen, QRxPharma is a dynamic company and maintains ongoing vigilance in the neuropharmacological marketplace to ensure that we best meet prescriber and patient needs.

After careful market analysis, consultations with pain physicians and the FDA and following advice from the Company's Scientific Advisory Board, we have decided to broaden the Company's reach in the treatment of moderate to severe pain by targeting Q8003IR development primarily towards the acute pain market. The treatment of

chronic pain remains a secondary opportunity, with the needs of these patients to be met primarily by Q8011CR, our second dual opioid.

This approach will position the Company well to take advantage of the significant prescription volume that exists in both the acute and chronic pain segments.

An added advantage of directing our primary dual opioid towards the acute pain market is that we can better leverage the pharmaceutical advantages of Q8001IR's immediate release formulation and bring it to market with reduced development expense.

Q8003IR and Q8011CR are complementary pain therapies and will address both acute and chronic pain so as to extend prescriber choice.

Since listing, QRxPharma has also made good progress in the development of our Torsin Program, especially through our strategic alliance with the University of Alabama, whose Caldwell Laboratory has embarked on a research program directed at re-engineeering existing drug therapies for new clinical applications including the treatment of dystonia, Parkinson's Disease and other neurological disorders.

This cutting edge research is supported by a number of professional bodies, including the Dystonia Medical Research Foundation and the Michael J. Fox Foundation for Parkinson's Research, which recognise the value of the Caldwell Laboratory's work.

Before handing over to John to provide an operational update I should comment briefly on the quality of the management team that QRxPharma has assembled.

It is no mean feat to manage effectively a Company listed in Sydney, with its CEO and Chairman based in the US and other Directors, Executives and Advisors spread across the globe. I pay tribute to John, Doug, Chris Campbell and their associates for ensuring that the Company's communication and decision-making is of the highest calibre and for never losing sight of the main game – to create value for shareholders by working to bring new drugs to the market so as to relieve human suffering.

John Holaday will now provide an update on the Company's operational progress.

Managing Director's Address – Dr John Holaday
2 November 2007

Ladies and gentlemen, the five months since QRxPharma listed on the ASX have been a productive period that has moved us significantly closer to our goal of commercialising our lead product candidate, Q8003IR, by 2010.

Our product portfolio includes late and early stage clinical candidates, with Q8003IR closest to the marketplace, and other treatments for the relief of pain and for the treatment of neurodegenerative diseases following close behind in the clinical pipeline.

The Company's principal therapies under development are our pain management drugs, Q8003IR (to begin Phase 3 trials shortly) and Q8011CR, which will complete Phase 1 studies in 2008. We anticipate that T9001, our drug to treat dystonia and Parkinson's disease, will also begin Phase 2 trials next year.

We are working to ensure that QRxPharma's pain relief dual opioid products (morphine plus oxycodone - invented at the University of Queensland) will become the 'gold standard' of drugs for the treatment of moderate to severe pain. They address a worldwide opioid market estimated to be US$10 billion globally, and will provide improved pain relief while at the same time minimising serious side-effects such as respiratory depression, constipation, nausea and sedation. As the Chairman has stated, we have refocused Q8003IR primarily on the relief of acute pain, with chronic pain as a secondary market.

Our milestone timetable for the launch of Q8003IR in the US market is proceeding well. Since the end of June this year we have:

- Completed product manufacturing of clinical supplies
- Finalised clinical trial protocols for an acute post-surgery trial and a safety extension clinical trial
- Selected our Clinical Research Organisation partner to conduct studies

- Selected clinical trial sites

- Received Institute Review Board (IRB) approval to proceed with a study of acute pain in post-surgical patients

I am very pleased to announce today that QRxPharma has recently received full clearance from the IRB to begin to enroll patients so we now are literally days away from our first Phase 3 trial sites being initiated.

This is exciting news for the Company. Let me acknowledge all of the efforts by the QRxPharma executive team that have brought us to this important milestone and give credit to the exceptional efforts of Doug Saltel, our COO, Warren Stern, our Exec. VP, Drug Development, Chris Campbell, our CFO and the rest of the team we have built to take QRxPharma from its initial growth since Dr. Gary Pace served as the founding CEO of the company, through our IPO and to the present time.

QRxPharma has been able to reach these milestones on time by leveraging its in-house regulatory, manufacturing and drug development knowledge. While focusing on the key priority of Q8003IR, we continue to progress the development of our second dual opioid drug, Q8011CR, leading to its Phase 1 clinical studies next year. On the business development front, we are moving forward with discussions to expand our 'go-to-market' strategy through relationships with other biopharmaceutical companies to create a global marketplace for our products.

One of the great strengths of the QRxPharma business model is that one third of the total (US) market for moderate to severe pain can be covered by approximately 150 salespeople, targeting pain specialists, pain clinics and high prescribing doctors. So when the time comes to embark on full-scale marketing, we will benefit greatly from these scale efficiencies that define the specialty pharmaceutical strategy.

Turning to the US$85 billion Central Nervous System market, our leading product candidate is T9001, a torsin-based therapeutic drug for treatment of the progressive brain diseases in patients suffering from Parkinson's Disease or dystonia.

As the Chairman noted, QRxPharma has formed a research alliance with the Caldwell Laboratory at the University of Alabama in the US. Their world-class research has revealed that certain antibiotic drugs, independent of their actions in killing bacteria, happen to activate an important protective mechanism in the brain to prevent the progression of neurodegenerative diseases. QRxPharma has an exclusive licence to this important patent portfolio of torsin inventions from the University. Supportive grants have been received from the National Institutes of Health in the US, as well as the National Science Foundation, Howard Hughes Medical Institution, and the Michael J. Fox Foundation. Additional grant applications were recently filed to augment the QRxPharma-sponsored research program with the Caldwell Laboratory.

QRxPharma has the requisite financial, scientific and human capital to achieve its objectives, as set out in our Prospectus, to bring Q8003IR through the FDA to approval, and Q8011CR to completion of Phase 1 studies next year. We can draw on a depth of relevant experience in:

- The integration of academic, scientific and commercial knowledge into targeted specialist-driven products
- Product R & D for both public and privately-held life sciences companies
- Product commercialisation
- Regulatory approval processes
- Managing and financing publicly traded companies

We are poised to execute, on time and on budget.

In summary, our objective is to make a difference in the lives of patients and build shareholder value as we focus product commercialisation to address the enormous markets of pain management and Central Nervous System disorders. Our business model is designed to shorten the transition from the laboratory to the market.

Our early and late stage drug development pipeline is proceeding according to plan and we are well-resourced to complete the Q8003IR Phase 3 trials and our NDA filing leading to product commercialisation in 2010, key objectives we set for the Company at the time of listing.

On behalf of the management team I thank the Board of QRxPharma and the Scientific Advisory Board for their unfailing support, and look forward to continued success as we build QRxPharma into a commercially ready, specialty pharmaceutical company.